Product Name

  • Name

    Mevastatin

  • EINECS 700-442-0
  • CAS No. 73573-88-3
  • Article Data18
  • CAS DataBase
  • Density 1.13 g/cm3
  • Solubility DMSO: 20 mg/mL
  • Melting Point 151-153 °C
  • Formula C23H34O5
  • Boiling Point 555 °C at 760 mmHg
  • Molecular Weight 390.52
  • Flash Point 186.5 °C
  • Transport Information
  • Appearance off-white solid
  • Safety 22-24/25-45-36/37/39
  • Risk Codes 26/27/28
  • Molecular Structure Molecular Structure of 73573-88-3 (Mevastatin)
  • Hazard Symbols VeryT+
  • Synonyms Butanoicacid, 2-methyl-,(1S,7S,8S,8αR)-1,2,3,7,8,8α-hexahydro-7-methyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenylester, (2S)-;Butanoicacid, 2-methyl-,1,2,3,7,8,8α-hexahydro-7-methyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenylester, [1S-[1α(R*),7b,8b(2S*,4S*),8ab]]-;Antibiotic ML 236B;CS 500;CS 500(antibiotic);Compactin;Compactin (Penicillium);L 637312;ML 236B;ML 236Blactone;NSC 281245;Statin I;
  • PSA 72.83000
  • LogP 3.94950

Synthetic route

(1S,2S,8S,8aR,3'R,5'R,2''S)-methyl 1,2,6,7,8,8a-hexahydro-3',5'-dihydroxy-2-methyl-8-<(2-methyl-1-oxobutyl)oxy>-1-naphthaleneheptanoate
79814-60-1

(1S,2S,8S,8aR,3'R,5'R,2''S)-methyl 1,2,6,7,8,8a-hexahydro-3',5'-dihydroxy-2-methyl-8-<(2-methyl-1-oxobutyl)oxy>-1-naphthaleneheptanoate

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
With toluene-4-sulfonic acid In benzene for 1.08333h; Ambient temperature;70%
With toluene-4-sulfonic acid In benzene70%
(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-[2-((2R,4R)-4,6-dihydroxy-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester
116996-42-0, 117065-49-3

(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-[2-((2R,4R)-4,6-dihydroxy-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
With Celite; silver carbonate In toluene at 95℃; for 2h;61%
(1S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-7-methyl-8-<2-((2R,4R)-tetrahydro-4-methoxy-6-oxo-2H-pyran-2-yl)-ethyl>-1-naphthyl (2S)-2-methylbutyrate
84751-53-1

(1S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-7-methyl-8-<2-((2R,4R)-tetrahydro-4-methoxy-6-oxo-2H-pyran-2-yl)-ethyl>-1-naphthyl (2S)-2-methylbutyrate

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
With boron tribromide In dichloromethane at -23℃; for 5h;31%
With boron tribromide In dichloromethane at -23℃; for 6h;31%
(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-(tert-butyl-diphenyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester
108713-03-7

(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-(tert-butyl-diphenyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
With hydrogen fluoride In water; acetonitrile at 45℃; for 8h;30%
(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester
87000-71-3

(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
With hydrogen fluoride In acetonitrile at 25℃; for 0.5h; Yield given;
(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-[2-((2R,4R,6S)-4,6-dihydroxy-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester
116996-42-0, 117065-49-3

(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-[2-((2R,4R,6S)-4,6-dihydroxy-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
With Celite; silver carbonate In toluene at 95℃; for 2h; Yield given;
3,5-Dihydroxy-7-[(1S,2S,8S,8aR)-2-methyl-8-((S)-2-methyl-butyryloxy)-1,2,6,7,8,8a-hexahydro-naphthalen-1-yl]-heptanoic acid methyl ester
67383-81-7, 79814-60-1, 79896-19-8, 79896-20-1, 79896-21-2, 109785-25-3, 109785-26-4

3,5-Dihydroxy-7-[(1S,2S,8S,8aR)-2-methyl-8-((S)-2-methyl-butyryloxy)-1,2,6,7,8,8a-hexahydro-naphthalen-1-yl]-heptanoic acid methyl ester

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
With toluene-4-sulfonic acid In benzene at 25℃; for 0.5h;
(R)-3,5-Dihydroxy-7-[(1S,2S,8S,8aR)-2-methyl-8-((S)-2-methyl-butyryloxy)-1,2,6,7,8,8a-hexahydro-naphthalen-1-yl]-heptanoic acid methyl ester
67383-81-7, 79814-60-1, 79896-19-8, 79896-20-1, 79896-21-2, 109785-25-3, 109785-26-4

(R)-3,5-Dihydroxy-7-[(1S,2S,8S,8aR)-2-methyl-8-((S)-2-methyl-butyryloxy)-1,2,6,7,8,8a-hexahydro-naphthalen-1-yl]-heptanoic acid methyl ester

A

mevastatin
73573-88-3

mevastatin

B

3,5-bis-epi-compactin
84173-31-9

3,5-bis-epi-compactin

Conditions
ConditionsYield
With toluene-4-sulfonic acid In benzene at 25℃; for 0.25h;A 32 mg
B 22 mg
methyl 3,5-dihydroxy-7-<(1'S,2'S,8'S,8a'S)-2'methyl-8'-<(S)-2-methylbutanoyloxy>-1',2',3',7',8',8a'-hexahydro-1'-naphthyl>heptanoate
67383-81-7, 79814-60-1, 79896-19-8, 79896-20-1, 79896-21-2, 109785-25-3, 109785-26-4

methyl 3,5-dihydroxy-7-<(1'S,2'S,8'S,8a'S)-2'methyl-8'-<(S)-2-methylbutanoyloxy>-1',2',3',7',8',8a'-hexahydro-1'-naphthyl>heptanoate

A

mevastatin
73573-88-3

mevastatin

B

3,5-bis-epi-compactin
84173-31-9

3,5-bis-epi-compactin

Conditions
ConditionsYield
With pyridine hydrogenfluoride In acetonitrile at 0℃; for 6h;A 15.6 mg
B 15.4 mg
(4S,6R)-4-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-6-[2-((1S,2S,8aR)-2-methyl-8-triethylsilanyloxy-1,2,6,7,8,8a-hexahydro-naphthalen-1-yl)-ethyl]-[1,3]dioxane
116996-36-2, 117065-47-1

(4S,6R)-4-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-6-[2-((1S,2S,8aR)-2-methyl-8-triethylsilanyloxy-1,2,6,7,8,8a-hexahydro-naphthalen-1-yl)-ethyl]-[1,3]dioxane

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1: 1.) HF; 2.) 2-methoxypropene / 2.) pyridinium p-toluenesulfonate / 1.) H2O, MeCN, r.t., 1.75 h; 2.) CH2Cl2, 0 deg C, 40 min
2: 1.) (COCl)2; 2.Et3N / 1.) DMSO, CH2Cl2, -78 deg C, 15 min; 2.) -78 deg C, 5 min
3: 80 percent / L-Selectride / tetrahydrofuran / -78 deg C, 1 h; -43 deg C, 12 h
4: 99 percent / Et3N / DMAP / CH2Cl2 / 68 h / Ambient temperature
5: 92 percent / Bu4NF / tetrahydrofuran / 1.75 h / Ambient temperature
6: 1.) (COCl)2; 2.) Et3N / 1.) DMSO,CH2Cl2, -78 deg C, 20 min; 2.) -78 deg C, 10 min, -78 deg C -> r.t., 30 min
7: 88 percent / 1.3N HCl / tetrahydrofuran / 2 h / Ambient temperature
8: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
Multi-step reaction with 8 steps
1: 1.) 48percent aq. HF, 2.) 2-methoxypropene, pyridinium p-toluenesulfonate / 1.) MeCN, RT, 1.75 h, 2.) CH2Cl2, 0 deg C, 40 min
2: 93 percent / (COCl)2, DMSO / CH2Cl2 / 0.25 h / -78 °C
3: 80 percent / L-Selectride / tetrahydrofuran / 1.) -78 deg C, 1 h, 2.) -43 deg C, 12 h
4: 99 percent / Et3N, 4-(dimethylamino)pyridine (DMAP) / CH2Cl2 / 68 h / Ambient temperature
5: 92 percent / Bu4N(1+)*F(1-) / tetrahydrofuran / 1.75 h / Ambient temperature
6: 91 percent / (COCl)2, DMSO / CH2Cl2 / 0.33 h / -78 °C
7: 88 percent / 10percent aq. HCl / tetrahydrofuran / 2 h / Ambient temperature
8: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
4-[(1S,5S,6S)-6-(2-{(4R,6S)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-5-methyl-2-oxo-cyclohex-3-enyl]-4-triethylsilanyloxy-butyraldehyde
116996-35-1, 117065-46-0

4-[(1S,5S,6S)-6-(2-{(4R,6S)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-5-methyl-2-oxo-cyclohex-3-enyl]-4-triethylsilanyloxy-butyraldehyde

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 9 steps
1: 85 percent / C8K, TiCl3 / 1,2-dimethoxy-ethane / r.t., 5 h; reflux, 3 h
2: 1.) HF; 2.) 2-methoxypropene / 2.) pyridinium p-toluenesulfonate / 1.) H2O, MeCN, r.t., 1.75 h; 2.) CH2Cl2, 0 deg C, 40 min
3: 1.) (COCl)2; 2.Et3N / 1.) DMSO, CH2Cl2, -78 deg C, 15 min; 2.) -78 deg C, 5 min
4: 80 percent / L-Selectride / tetrahydrofuran / -78 deg C, 1 h; -43 deg C, 12 h
5: 99 percent / Et3N / DMAP / CH2Cl2 / 68 h / Ambient temperature
6: 92 percent / Bu4NF / tetrahydrofuran / 1.75 h / Ambient temperature
7: 1.) (COCl)2; 2.) Et3N / 1.) DMSO,CH2Cl2, -78 deg C, 20 min; 2.) -78 deg C, 10 min, -78 deg C -> r.t., 30 min
8: 88 percent / 1.3N HCl / tetrahydrofuran / 2 h / Ambient temperature
9: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
Multi-step reaction with 9 steps
1: 85 percent / C8K, TiCl3 / 1,2-dimethoxy-ethane / 1.) RT, 5 h, 2.) reflux, 3 h
2: 1.) 48percent aq. HF, 2.) 2-methoxypropene, pyridinium p-toluenesulfonate / 1.) MeCN, RT, 1.75 h, 2.) CH2Cl2, 0 deg C, 40 min
3: 93 percent / (COCl)2, DMSO / CH2Cl2 / 0.25 h / -78 °C
4: 80 percent / L-Selectride / tetrahydrofuran / 1.) -78 deg C, 1 h, 2.) -43 deg C, 12 h
5: 99 percent / Et3N, 4-(dimethylamino)pyridine (DMAP) / CH2Cl2 / 68 h / Ambient temperature
6: 92 percent / Bu4N(1+)*F(1-) / tetrahydrofuran / 1.75 h / Ambient temperature
7: 91 percent / (COCl)2, DMSO / CH2Cl2 / 0.33 h / -78 °C
8: 88 percent / 10percent aq. HCl / tetrahydrofuran / 2 h / Ambient temperature
9: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-{2-[(4R,6S)-6-(2-hydroxy-ethyl)-2,2-dimethyl-[1,3]dioxan-4-yl]-ethyl}-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester
116996-40-8

(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-{2-[(4R,6S)-6-(2-hydroxy-ethyl)-2,2-dimethyl-[1,3]dioxan-4-yl]-ethyl}-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 1.) (COCl)2; 2.) Et3N / 1.) DMSO,CH2Cl2, -78 deg C, 20 min; 2.) -78 deg C, 10 min, -78 deg C -> r.t., 30 min
2: 88 percent / 1.3N HCl / tetrahydrofuran / 2 h / Ambient temperature
3: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
Multi-step reaction with 3 steps
1: 91 percent / (COCl)2, DMSO / CH2Cl2 / 0.33 h / -78 °C
2: 88 percent / 10percent aq. HCl / tetrahydrofuran / 2 h / Ambient temperature
3: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-{2-[(4R,6R)-2,2-dimethyl-6-(2-oxo-ethyl)-[1,3]dioxan-4-yl]-ethyl}-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester
116996-41-9

(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-{2-[(4R,6R)-2,2-dimethyl-6-(2-oxo-ethyl)-[1,3]dioxan-4-yl]-ethyl}-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 88 percent / 1.3N HCl / tetrahydrofuran / 2 h / Ambient temperature
2: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
Multi-step reaction with 2 steps
1: 88 percent / 10percent aq. HCl / tetrahydrofuran / 2 h / Ambient temperature
2: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
<4R-<4α*(1R*,2S*)>6α>>-6-<2-<<(1,1-dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-α-(2-methyl-5-oxo-3-cyclohexen-1-yl)-1,3-dioxane-4-propanal
116996-31-7, 126060-10-4

<4R-<4α*(1R*,2S*)>6α>>-6-<2-<<(1,1-dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-α-(2-methyl-5-oxo-3-cyclohexen-1-yl)-1,3-dioxane-4-propanal

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 13 steps
1: 50 percent / (Ph3P)3RhCl / toluene; acetonitrile / 2.5 h / Heating
2: 1.) LDA / 1.) Et2O, -78 deg C, 1 h; 2.) -78 deg C, 10 min
3: 96 percent / i-Pr2NH / DMAP / diethyl ether / 36 h / Ambient temperature
4: 1.) O3; 2.) Ph3P / 1.) CH2Cl2, -78 deg C; 2.) -78 deg C, 20 min, r.t., 8 h
5: 85 percent / C8K, TiCl3 / 1,2-dimethoxy-ethane / r.t., 5 h; reflux, 3 h
6: 1.) HF; 2.) 2-methoxypropene / 2.) pyridinium p-toluenesulfonate / 1.) H2O, MeCN, r.t., 1.75 h; 2.) CH2Cl2, 0 deg C, 40 min
7: 1.) (COCl)2; 2.Et3N / 1.) DMSO, CH2Cl2, -78 deg C, 15 min; 2.) -78 deg C, 5 min
8: 80 percent / L-Selectride / tetrahydrofuran / -78 deg C, 1 h; -43 deg C, 12 h
9: 99 percent / Et3N / DMAP / CH2Cl2 / 68 h / Ambient temperature
10: 92 percent / Bu4NF / tetrahydrofuran / 1.75 h / Ambient temperature
11: 1.) (COCl)2; 2.) Et3N / 1.) DMSO,CH2Cl2, -78 deg C, 20 min; 2.) -78 deg C, 10 min, -78 deg C -> r.t., 30 min
12: 88 percent / 1.3N HCl / tetrahydrofuran / 2 h / Ambient temperature
13: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
Multi-step reaction with 13 steps
1: 50 percent / (Ph3P)3RhCl / toluene; benzonitrile / 2.5 h / Heating
2: 1.) lithium diisopropylamide (LDA) / 1.) Et2O, -78 deg C, 1 h, 2.) -78 deg C, 10 min
3: 96 percent / i-Pr2NH, 4-(dimethylamino)pyridine (DMAP) / diethyl ether / 36 h / Ambient temperature
4: 1.) O3, 2.) Ph3P / 1.) CH2Cl2, -78 deg C, 20 min, 2.) RT, 8 h
5: 85 percent / C8K, TiCl3 / 1,2-dimethoxy-ethane / 1.) RT, 5 h, 2.) reflux, 3 h
6: 1.) 48percent aq. HF, 2.) 2-methoxypropene, pyridinium p-toluenesulfonate / 1.) MeCN, RT, 1.75 h, 2.) CH2Cl2, 0 deg C, 40 min
7: 93 percent / (COCl)2, DMSO / CH2Cl2 / 0.25 h / -78 °C
8: 80 percent / L-Selectride / tetrahydrofuran / 1.) -78 deg C, 1 h, 2.) -43 deg C, 12 h
9: 99 percent / Et3N, 4-(dimethylamino)pyridine (DMAP) / CH2Cl2 / 68 h / Ambient temperature
10: 92 percent / Bu4N(1+)*F(1-) / tetrahydrofuran / 1.75 h / Ambient temperature
11: 91 percent / (COCl)2, DMSO / CH2Cl2 / 0.33 h / -78 °C
12: 88 percent / 10percent aq. HCl / tetrahydrofuran / 2 h / Ambient temperature
13: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
(7S,8S,8aR)-8-(2-{(4R,6S)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-7-methyl-3,7,8,8a-tetrahydro-2H-naphthalen-1-one
116996-38-4

(7S,8S,8aR)-8-(2-{(4R,6S)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-7-methyl-3,7,8,8a-tetrahydro-2H-naphthalen-1-one

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 80 percent / L-Selectride / tetrahydrofuran / -78 deg C, 1 h; -43 deg C, 12 h
2: 99 percent / Et3N / DMAP / CH2Cl2 / 68 h / Ambient temperature
3: 92 percent / Bu4NF / tetrahydrofuran / 1.75 h / Ambient temperature
4: 1.) (COCl)2; 2.) Et3N / 1.) DMSO,CH2Cl2, -78 deg C, 20 min; 2.) -78 deg C, 10 min, -78 deg C -> r.t., 30 min
5: 88 percent / 1.3N HCl / tetrahydrofuran / 2 h / Ambient temperature
6: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
Multi-step reaction with 6 steps
1: 80 percent / L-Selectride / tetrahydrofuran / 1.) -78 deg C, 1 h, 2.) -43 deg C, 12 h
2: 99 percent / Et3N, 4-(dimethylamino)pyridine (DMAP) / CH2Cl2 / 68 h / Ambient temperature
3: 92 percent / Bu4N(1+)*F(1-) / tetrahydrofuran / 1.75 h / Ambient temperature
4: 91 percent / (COCl)2, DMSO / CH2Cl2 / 0.33 h / -78 °C
5: 88 percent / 10percent aq. HCl / tetrahydrofuran / 2 h / Ambient temperature
6: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
(4S,5S,6S)-5-(2-{(4R,6S)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-6-(1-hydroxy-pent-4-enyl)-4-methyl-cyclohex-2-enone
116996-33-9, 117065-44-8

(4S,5S,6S)-5-(2-{(4R,6S)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-6-(1-hydroxy-pent-4-enyl)-4-methyl-cyclohex-2-enone

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 11 steps
1: 96 percent / i-Pr2NH / DMAP / diethyl ether / 36 h / Ambient temperature
2: 1.) O3; 2.) Ph3P / 1.) CH2Cl2, -78 deg C; 2.) -78 deg C, 20 min, r.t., 8 h
3: 85 percent / C8K, TiCl3 / 1,2-dimethoxy-ethane / r.t., 5 h; reflux, 3 h
4: 1.) HF; 2.) 2-methoxypropene / 2.) pyridinium p-toluenesulfonate / 1.) H2O, MeCN, r.t., 1.75 h; 2.) CH2Cl2, 0 deg C, 40 min
5: 1.) (COCl)2; 2.Et3N / 1.) DMSO, CH2Cl2, -78 deg C, 15 min; 2.) -78 deg C, 5 min
6: 80 percent / L-Selectride / tetrahydrofuran / -78 deg C, 1 h; -43 deg C, 12 h
7: 99 percent / Et3N / DMAP / CH2Cl2 / 68 h / Ambient temperature
8: 92 percent / Bu4NF / tetrahydrofuran / 1.75 h / Ambient temperature
9: 1.) (COCl)2; 2.) Et3N / 1.) DMSO,CH2Cl2, -78 deg C, 20 min; 2.) -78 deg C, 10 min, -78 deg C -> r.t., 30 min
10: 88 percent / 1.3N HCl / tetrahydrofuran / 2 h / Ambient temperature
11: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
Multi-step reaction with 11 steps
1: 96 percent / i-Pr2NH, 4-(dimethylamino)pyridine (DMAP) / diethyl ether / 36 h / Ambient temperature
2: 1.) O3, 2.) Ph3P / 1.) CH2Cl2, -78 deg C, 20 min, 2.) RT, 8 h
3: 85 percent / C8K, TiCl3 / 1,2-dimethoxy-ethane / 1.) RT, 5 h, 2.) reflux, 3 h
4: 1.) 48percent aq. HF, 2.) 2-methoxypropene, pyridinium p-toluenesulfonate / 1.) MeCN, RT, 1.75 h, 2.) CH2Cl2, 0 deg C, 40 min
5: 93 percent / (COCl)2, DMSO / CH2Cl2 / 0.25 h / -78 °C
6: 80 percent / L-Selectride / tetrahydrofuran / 1.) -78 deg C, 1 h, 2.) -43 deg C, 12 h
7: 99 percent / Et3N, 4-(dimethylamino)pyridine (DMAP) / CH2Cl2 / 68 h / Ambient temperature
8: 92 percent / Bu4N(1+)*F(1-) / tetrahydrofuran / 1.75 h / Ambient temperature
9: 91 percent / (COCl)2, DMSO / CH2Cl2 / 0.33 h / -78 °C
10: 88 percent / 10percent aq. HCl / tetrahydrofuran / 2 h / Ambient temperature
11: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-(2-{(4R,6S)-6-[2-(tert-butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester
116996-39-5

(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-(2-{(4R,6S)-6-[2-(tert-butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 92 percent / Bu4NF / tetrahydrofuran / 1.75 h / Ambient temperature
2: 1.) (COCl)2; 2.) Et3N / 1.) DMSO,CH2Cl2, -78 deg C, 20 min; 2.) -78 deg C, 10 min, -78 deg C -> r.t., 30 min
3: 88 percent / 1.3N HCl / tetrahydrofuran / 2 h / Ambient temperature
4: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
Multi-step reaction with 4 steps
1: 92 percent / Bu4N(1+)*F(1-) / tetrahydrofuran / 1.75 h / Ambient temperature
2: 91 percent / (COCl)2, DMSO / CH2Cl2 / 0.33 h / -78 °C
3: 88 percent / 10percent aq. HCl / tetrahydrofuran / 2 h / Ambient temperature
4: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
(4S,5S,6S)-5-(2-{(4R,6S)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-4-methyl-6-(1-triethylsilanyloxy-pent-4-enyl)-cyclohex-2-enone
116996-34-0, 117065-45-9

(4S,5S,6S)-5-(2-{(4R,6S)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-4-methyl-6-(1-triethylsilanyloxy-pent-4-enyl)-cyclohex-2-enone

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 10 steps
1: 1.) O3; 2.) Ph3P / 1.) CH2Cl2, -78 deg C; 2.) -78 deg C, 20 min, r.t., 8 h
2: 85 percent / C8K, TiCl3 / 1,2-dimethoxy-ethane / r.t., 5 h; reflux, 3 h
3: 1.) HF; 2.) 2-methoxypropene / 2.) pyridinium p-toluenesulfonate / 1.) H2O, MeCN, r.t., 1.75 h; 2.) CH2Cl2, 0 deg C, 40 min
4: 1.) (COCl)2; 2.Et3N / 1.) DMSO, CH2Cl2, -78 deg C, 15 min; 2.) -78 deg C, 5 min
5: 80 percent / L-Selectride / tetrahydrofuran / -78 deg C, 1 h; -43 deg C, 12 h
6: 99 percent / Et3N / DMAP / CH2Cl2 / 68 h / Ambient temperature
7: 92 percent / Bu4NF / tetrahydrofuran / 1.75 h / Ambient temperature
8: 1.) (COCl)2; 2.) Et3N / 1.) DMSO,CH2Cl2, -78 deg C, 20 min; 2.) -78 deg C, 10 min, -78 deg C -> r.t., 30 min
9: 88 percent / 1.3N HCl / tetrahydrofuran / 2 h / Ambient temperature
10: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
Multi-step reaction with 10 steps
1: 1.) O3, 2.) Ph3P / 1.) CH2Cl2, -78 deg C, 20 min, 2.) RT, 8 h
2: 85 percent / C8K, TiCl3 / 1,2-dimethoxy-ethane / 1.) RT, 5 h, 2.) reflux, 3 h
3: 1.) 48percent aq. HF, 2.) 2-methoxypropene, pyridinium p-toluenesulfonate / 1.) MeCN, RT, 1.75 h, 2.) CH2Cl2, 0 deg C, 40 min
4: 93 percent / (COCl)2, DMSO / CH2Cl2 / 0.25 h / -78 °C
5: 80 percent / L-Selectride / tetrahydrofuran / 1.) -78 deg C, 1 h, 2.) -43 deg C, 12 h
6: 99 percent / Et3N, 4-(dimethylamino)pyridine (DMAP) / CH2Cl2 / 68 h / Ambient temperature
7: 92 percent / Bu4N(1+)*F(1-) / tetrahydrofuran / 1.75 h / Ambient temperature
8: 91 percent / (COCl)2, DMSO / CH2Cl2 / 0.33 h / -78 °C
9: 88 percent / 10percent aq. HCl / tetrahydrofuran / 2 h / Ambient temperature
10: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
<4R-<4α(4R*,5R*),6α>>-5-<2-<6-<2-<<(1,1-dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-4-methyl-2-cyclohexen-1-one
116996-32-8

<4R-<4α(4R*,5R*),6α>>-5-<2-<6-<2-<<(1,1-dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-4-methyl-2-cyclohexen-1-one

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 12 steps
1: 1.) LDA / 1.) Et2O, -78 deg C, 1 h; 2.) -78 deg C, 10 min
2: 96 percent / i-Pr2NH / DMAP / diethyl ether / 36 h / Ambient temperature
3: 1.) O3; 2.) Ph3P / 1.) CH2Cl2, -78 deg C; 2.) -78 deg C, 20 min, r.t., 8 h
4: 85 percent / C8K, TiCl3 / 1,2-dimethoxy-ethane / r.t., 5 h; reflux, 3 h
5: 1.) HF; 2.) 2-methoxypropene / 2.) pyridinium p-toluenesulfonate / 1.) H2O, MeCN, r.t., 1.75 h; 2.) CH2Cl2, 0 deg C, 40 min
6: 1.) (COCl)2; 2.Et3N / 1.) DMSO, CH2Cl2, -78 deg C, 15 min; 2.) -78 deg C, 5 min
7: 80 percent / L-Selectride / tetrahydrofuran / -78 deg C, 1 h; -43 deg C, 12 h
8: 99 percent / Et3N / DMAP / CH2Cl2 / 68 h / Ambient temperature
9: 92 percent / Bu4NF / tetrahydrofuran / 1.75 h / Ambient temperature
10: 1.) (COCl)2; 2.) Et3N / 1.) DMSO,CH2Cl2, -78 deg C, 20 min; 2.) -78 deg C, 10 min, -78 deg C -> r.t., 30 min
11: 88 percent / 1.3N HCl / tetrahydrofuran / 2 h / Ambient temperature
12: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
Multi-step reaction with 12 steps
1: 1.) lithium diisopropylamide (LDA) / 1.) Et2O, -78 deg C, 1 h, 2.) -78 deg C, 10 min
2: 96 percent / i-Pr2NH, 4-(dimethylamino)pyridine (DMAP) / diethyl ether / 36 h / Ambient temperature
3: 1.) O3, 2.) Ph3P / 1.) CH2Cl2, -78 deg C, 20 min, 2.) RT, 8 h
4: 85 percent / C8K, TiCl3 / 1,2-dimethoxy-ethane / 1.) RT, 5 h, 2.) reflux, 3 h
5: 1.) 48percent aq. HF, 2.) 2-methoxypropene, pyridinium p-toluenesulfonate / 1.) MeCN, RT, 1.75 h, 2.) CH2Cl2, 0 deg C, 40 min
6: 93 percent / (COCl)2, DMSO / CH2Cl2 / 0.25 h / -78 °C
7: 80 percent / L-Selectride / tetrahydrofuran / 1.) -78 deg C, 1 h, 2.) -43 deg C, 12 h
8: 99 percent / Et3N, 4-(dimethylamino)pyridine (DMAP) / CH2Cl2 / 68 h / Ambient temperature
9: 92 percent / Bu4N(1+)*F(1-) / tetrahydrofuran / 1.75 h / Ambient temperature
10: 91 percent / (COCl)2, DMSO / CH2Cl2 / 0.33 h / -78 °C
11: 88 percent / 10percent aq. HCl / tetrahydrofuran / 2 h / Ambient temperature
12: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
(7S,8S,8aR)-8-(2-{(4R,6S)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-ol
116996-37-3, 117065-48-2

(7S,8S,8aR)-8-(2-{(4R,6S)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-ol

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: 1.) (COCl)2; 2.Et3N / 1.) DMSO, CH2Cl2, -78 deg C, 15 min; 2.) -78 deg C, 5 min
2: 80 percent / L-Selectride / tetrahydrofuran / -78 deg C, 1 h; -43 deg C, 12 h
3: 99 percent / Et3N / DMAP / CH2Cl2 / 68 h / Ambient temperature
4: 92 percent / Bu4NF / tetrahydrofuran / 1.75 h / Ambient temperature
5: 1.) (COCl)2; 2.) Et3N / 1.) DMSO,CH2Cl2, -78 deg C, 20 min; 2.) -78 deg C, 10 min, -78 deg C -> r.t., 30 min
6: 88 percent / 1.3N HCl / tetrahydrofuran / 2 h / Ambient temperature
7: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
Multi-step reaction with 7 steps
1: 93 percent / (COCl)2, DMSO / CH2Cl2 / 0.25 h / -78 °C
2: 80 percent / L-Selectride / tetrahydrofuran / 1.) -78 deg C, 1 h, 2.) -43 deg C, 12 h
3: 99 percent / Et3N, 4-(dimethylamino)pyridine (DMAP) / CH2Cl2 / 68 h / Ambient temperature
4: 92 percent / Bu4N(1+)*F(1-) / tetrahydrofuran / 1.75 h / Ambient temperature
5: 91 percent / (COCl)2, DMSO / CH2Cl2 / 0.33 h / -78 °C
6: 88 percent / 10percent aq. HCl / tetrahydrofuran / 2 h / Ambient temperature
7: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
<1S-<1α,7β,8β(4S*,6R*),8aβ>>-8-<2-<6-<2-<<(1,1-Dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-1,2,6,7,8,8a-hexahydro-7-methyl-1-naphthalenol
117065-48-2

<1S-<1α,7β,8β(4S*,6R*),8aβ>>-8-<2-<6-<2-<<(1,1-Dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-1,2,6,7,8,8a-hexahydro-7-methyl-1-naphthalenol

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 99 percent / Et3N / DMAP / CH2Cl2 / 68 h / Ambient temperature
2: 92 percent / Bu4NF / tetrahydrofuran / 1.75 h / Ambient temperature
3: 1.) (COCl)2; 2.) Et3N / 1.) DMSO,CH2Cl2, -78 deg C, 20 min; 2.) -78 deg C, 10 min, -78 deg C -> r.t., 30 min
4: 88 percent / 1.3N HCl / tetrahydrofuran / 2 h / Ambient temperature
5: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
Multi-step reaction with 5 steps
1: 99 percent / Et3N, 4-(dimethylamino)pyridine (DMAP) / CH2Cl2 / 68 h / Ambient temperature
2: 92 percent / Bu4N(1+)*F(1-) / tetrahydrofuran / 1.75 h / Ambient temperature
3: 91 percent / (COCl)2, DMSO / CH2Cl2 / 0.33 h / -78 °C
4: 88 percent / 10percent aq. HCl / tetrahydrofuran / 2 h / Ambient temperature
5: 61 percent / Ag2CO3/Celite / toluene / 2 h / 95 °C
View Scheme
(R)-3-<(tert-butyldimethylsilyl)oxy>-6-(dimethoxyphosphinyl)-5-oxohexanoic acid
96555-55-4

(R)-3-<(tert-butyldimethylsilyl)oxy>-6-(dimethoxyphosphinyl)-5-oxohexanoic acid

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 92 percent / diethyl ether / 0.25 h / Ambient temperature
2: 55 percent / LiCl, 1,8-diazabicyclo<5.4.0>undec-7-ene (DBU) / dimethylsulfoxide / 30 h / Ambient temperature
3: (Ph3P)3RhCl, Et3SiH / benzene / 0.58 h / 70 °C
4: aq. HF / acetonitrile / 0.83 h / Ambient temperature
5: 9.6 mg / NaBH4 / methanol / 0.45 h / -15 - -13 °C
6: 70 percent / p-TsOH*H2O / benzene / 1.08 h / Ambient temperature
View Scheme
Multi-step reaction with 6 steps
2: LiCl/DBU / acetonitrile
3: Et3SiH/(Ph3p)3ClRh / toluene / 65 °C
4: HF / acetonitrile
5: NaBH4 / 0.5 h / -15 °C
6: 70 percent / p-TsOH / benzene
View Scheme
(R)-6-(Dimethoxyphosphinyl)-3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-oxohexanoic acid, methylester
96555-58-7

(R)-6-(Dimethoxyphosphinyl)-3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-oxohexanoic acid, methylester

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 55 percent / LiCl, 1,8-diazabicyclo<5.4.0>undec-7-ene (DBU) / dimethylsulfoxide / 30 h / Ambient temperature
2: (Ph3P)3RhCl, Et3SiH / benzene / 0.58 h / 70 °C
3: aq. HF / acetonitrile / 0.83 h / Ambient temperature
4: 9.6 mg / NaBH4 / methanol / 0.45 h / -15 - -13 °C
5: 70 percent / p-TsOH*H2O / benzene / 1.08 h / Ambient temperature
View Scheme
Multi-step reaction with 5 steps
1: LiCl/DBU / acetonitrile
2: Et3SiH/(Ph3p)3ClRh / toluene / 65 °C
3: HF / acetonitrile
4: NaBH4 / 0.5 h / -15 °C
5: 70 percent / p-TsOH / benzene
View Scheme
(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-formyl-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester
96575-19-8

(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-formyl-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 55 percent / LiCl, 1,8-diazabicyclo<5.4.0>undec-7-ene (DBU) / dimethylsulfoxide / 30 h / Ambient temperature
2: (Ph3P)3RhCl, Et3SiH / benzene / 0.58 h / 70 °C
3: aq. HF / acetonitrile / 0.83 h / Ambient temperature
4: 9.6 mg / NaBH4 / methanol / 0.45 h / -15 - -13 °C
5: 70 percent / p-TsOH*H2O / benzene / 1.08 h / Ambient temperature
View Scheme
Multi-step reaction with 5 steps
1: LiCl/DBU / acetonitrile
2: Et3SiH/(Ph3p)3ClRh / toluene / 65 °C
3: HF / acetonitrile
4: NaBH4 / 0.5 h / -15 °C
5: 70 percent / p-TsOH / benzene
View Scheme
(3R,1'R)-methyl 1'-phenylethyl 3-hydroxypentanedioate
96575-20-1

(3R,1'R)-methyl 1'-phenylethyl 3-hydroxypentanedioate

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 9 steps
1: 1.) N-BuLi / 1.) THF, hexane, -78 deg C, 15 min, 2.) THF, hexane, from -78 deg C to RT
2: 84 percent / imidazole / CH2Cl2 / 8 h / Ambient temperature
3: H2 / 10percent Pd/C / diethyl ether / 2 h / 760 Torr / Ambient temperature
4: 92 percent / diethyl ether / 0.25 h / Ambient temperature
5: 55 percent / LiCl, 1,8-diazabicyclo<5.4.0>undec-7-ene (DBU) / dimethylsulfoxide / 30 h / Ambient temperature
6: (Ph3P)3RhCl, Et3SiH / benzene / 0.58 h / 70 °C
7: aq. HF / acetonitrile / 0.83 h / Ambient temperature
8: 9.6 mg / NaBH4 / methanol / 0.45 h / -15 - -13 °C
9: 70 percent / p-TsOH*H2O / benzene / 1.08 h / Ambient temperature
View Scheme
Multi-step reaction with 9 steps
1: 43 percent / tetrahydrofuran / 0.17 h / -78 °C
2: C3H4N2
3: H2 / Pd-C
5: LiCl/DBU / acetonitrile
6: Et3SiH/(Ph3p)3ClRh / toluene / 65 °C
7: HF / acetonitrile
8: NaBH4 / 0.5 h / -15 °C
9: 70 percent / p-TsOH / benzene
View Scheme
(3R,1'R)-methyl 1'-phenylethyl 3-<(tert-butyldimethylsilyl)oxy>pentanedioate
96555-51-0

(3R,1'R)-methyl 1'-phenylethyl 3-<(tert-butyldimethylsilyl)oxy>pentanedioate

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 10 steps
1: 99 percent / aq. HF / acetonitrile / 1.25 h / Ambient temperature
2: 1.) N-BuLi / 1.) THF, hexane, -78 deg C, 15 min, 2.) THF, hexane, from -78 deg C to RT
3: 84 percent / imidazole / CH2Cl2 / 8 h / Ambient temperature
4: H2 / 10percent Pd/C / diethyl ether / 2 h / 760 Torr / Ambient temperature
5: 92 percent / diethyl ether / 0.25 h / Ambient temperature
6: 55 percent / LiCl, 1,8-diazabicyclo<5.4.0>undec-7-ene (DBU) / dimethylsulfoxide / 30 h / Ambient temperature
7: (Ph3P)3RhCl, Et3SiH / benzene / 0.58 h / 70 °C
8: aq. HF / acetonitrile / 0.83 h / Ambient temperature
9: 9.6 mg / NaBH4 / methanol / 0.45 h / -15 - -13 °C
10: 70 percent / p-TsOH*H2O / benzene / 1.08 h / Ambient temperature
View Scheme
Multi-step reaction with 10 steps
1: HF / acetonitrile
2: 43 percent / tetrahydrofuran / 0.17 h / -78 °C
3: C3H4N2
4: H2 / Pd-C
6: LiCl/DBU / acetonitrile
7: Et3SiH/(Ph3p)3ClRh / toluene / 65 °C
8: HF / acetonitrile
9: NaBH4 / 0.5 h / -15 °C
10: 70 percent / p-TsOH / benzene
View Scheme
(R)-dimethyl <<4-<<(R)-phenylethoxy>carbonyl>-3-hydroxybutyryl>methyl>phosphonate
96555-53-2

(R)-dimethyl <<4-<<(R)-phenylethoxy>carbonyl>-3-hydroxybutyryl>methyl>phosphonate

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1: 84 percent / imidazole / CH2Cl2 / 8 h / Ambient temperature
2: H2 / 10percent Pd/C / diethyl ether / 2 h / 760 Torr / Ambient temperature
3: 92 percent / diethyl ether / 0.25 h / Ambient temperature
4: 55 percent / LiCl, 1,8-diazabicyclo<5.4.0>undec-7-ene (DBU) / dimethylsulfoxide / 30 h / Ambient temperature
5: (Ph3P)3RhCl, Et3SiH / benzene / 0.58 h / 70 °C
6: aq. HF / acetonitrile / 0.83 h / Ambient temperature
7: 9.6 mg / NaBH4 / methanol / 0.45 h / -15 - -13 °C
8: 70 percent / p-TsOH*H2O / benzene / 1.08 h / Ambient temperature
View Scheme
Multi-step reaction with 8 steps
1: C3H4N2
2: H2 / Pd-C
4: LiCl/DBU / acetonitrile
5: Et3SiH/(Ph3p)3ClRh / toluene / 65 °C
6: HF / acetonitrile
7: NaBH4 / 0.5 h / -15 °C
8: 70 percent / p-TsOH / benzene
View Scheme
(R)-dimethyl <<3-<(tert-butyldimethylsilyl)oxy>-4-<<(R)-phenylethoxy>carbonyl>butyryl>methyl>phosphonate
96555-54-3

(R)-dimethyl <<3-<(tert-butyldimethylsilyl)oxy>-4-<<(R)-phenylethoxy>carbonyl>butyryl>methyl>phosphonate

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: H2 / 10percent Pd/C / diethyl ether / 2 h / 760 Torr / Ambient temperature
2: 92 percent / diethyl ether / 0.25 h / Ambient temperature
3: 55 percent / LiCl, 1,8-diazabicyclo<5.4.0>undec-7-ene (DBU) / dimethylsulfoxide / 30 h / Ambient temperature
4: (Ph3P)3RhCl, Et3SiH / benzene / 0.58 h / 70 °C
5: aq. HF / acetonitrile / 0.83 h / Ambient temperature
6: 9.6 mg / NaBH4 / methanol / 0.45 h / -15 - -13 °C
7: 70 percent / p-TsOH*H2O / benzene / 1.08 h / Ambient temperature
View Scheme
Multi-step reaction with 7 steps
1: H2 / Pd-C
3: LiCl/DBU / acetonitrile
4: Et3SiH/(Ph3p)3ClRh / toluene / 65 °C
5: HF / acetonitrile
6: NaBH4 / 0.5 h / -15 °C
7: 70 percent / p-TsOH / benzene
View Scheme
(1S,2S,8S,8aR,5'R,2''S)-methyl 1,2,6,7,8,8a-hexahydro-5'hydroxy-2-methyl-8-<(2-methyl-1-oxobutyl)oxy>-3'-oxo-1-naphthaleneheptanoate
96555-61-2

(1S,2S,8S,8aR,5'R,2''S)-methyl 1,2,6,7,8,8a-hexahydro-5'hydroxy-2-methyl-8-<(2-methyl-1-oxobutyl)oxy>-3'-oxo-1-naphthaleneheptanoate

mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 9.6 mg / NaBH4 / methanol / 0.45 h / -15 - -13 °C
2: 70 percent / p-TsOH*H2O / benzene / 1.08 h / Ambient temperature
View Scheme
Multi-step reaction with 2 steps
1: NaBH4 / 0.5 h / -15 °C
2: 70 percent / p-TsOH / benzene
View Scheme
mevastatin
73573-88-3

mevastatin

Conditions
ConditionsYield
85.4%
Product distribution / selectivity;
mevastatin
73573-88-3

mevastatin

<1S-<1α(3R*,5S*),2α,8β,8aα>>-7-(1,2,6,7,8,8a-Hexahydro-8-hydroxy-2-methyl-1-naphthalenyl)-1,3,5-heptanetriol
161466-60-0

<1S-<1α(3R*,5S*),2α,8β,8aα>>-7-(1,2,6,7,8,8a-Hexahydro-8-hydroxy-2-methyl-1-naphthalenyl)-1,3,5-heptanetriol

Conditions
ConditionsYield
With lithium aluminium tetrahydride In tetrahydrofuran for 9h; Ambient temperature;81%
With lithium aluminium tetrahydride In diethyl ether
mevastatin
73573-88-3

mevastatin

6-desmethylmonacolin J
58889-19-3

6-desmethylmonacolin J

Conditions
ConditionsYield
With lithium hydroxide for 24h; Heating;75%
Multi-step reaction with 2 steps
1: aq. LiOH / 24 h / Heating
2: 30 mg / toluene / 1 h / Heating
View Scheme
mevastatin
73573-88-3

mevastatin

(1S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-7-methyl-8-<2-((2R,4R)-tetrahydro-4-methoxy-6-oxo-2H-pyran-2-yl)-ethyl>-1-naphthyl (2S)-2-methylbutyrate
84751-53-1

(1S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-7-methyl-8-<2-((2R,4R)-tetrahydro-4-methoxy-6-oxo-2H-pyran-2-yl)-ethyl>-1-naphthyl (2S)-2-methylbutyrate

Conditions
ConditionsYield
In diethyl ether; water at 0℃;38%
formic acid
64-18-6

formic acid

mevastatin
73573-88-3

mevastatin

(S)-2-Methyl-butyric acid (1S,4S,6S,7R,8S,8aR)-4-chloro-6-formyloxy-8-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,4,6,7,8,8a-octahydro-naphthalen-1-yl ester
153079-18-6

(S)-2-Methyl-butyric acid (1S,4S,6S,7R,8S,8aR)-4-chloro-6-formyloxy-8-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,4,6,7,8,8a-octahydro-naphthalen-1-yl ester

Conditions
ConditionsYield
With tert-butylhypochlorite In dichloromethane at -10℃; Product distribution; Mechanism; reactions 1 or 2 equiv. terc-BuOCl;
With tert-butylhypochlorite In dichloromethane at -10℃;
formic acid
64-18-6

formic acid

mevastatin
73573-88-3

mevastatin

(S)-2-Methyl-butyric acid (1S,4S,5R,6S,7R,8S)-4,5-dichloro-6-formyloxy-8-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,4,5,6,7,8-octahydro-naphthalen-1-yl ester

(S)-2-Methyl-butyric acid (1S,4S,5R,6S,7R,8S)-4,5-dichloro-6-formyloxy-8-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,4,5,6,7,8-octahydro-naphthalen-1-yl ester

Conditions
ConditionsYield
With tert-butylhypochlorite In dichloromethane at -10℃;
mevastatin
73573-88-3

mevastatin

anhydrocompactin
84173-32-0

anhydrocompactin

Conditions
ConditionsYield
With potassium hydrogensulfate In N,N-dimethyl-formamide for 6h; Heating;2.7 mg
tert-butoxy radical
3141-58-0

tert-butoxy radical

mevastatin
73573-88-3

mevastatin

A

acetone
67-64-1

acetone

B

tert-butyl alcohol
75-65-0

tert-butyl alcohol

Conditions
ConditionsYield
In acetonitrile at 40℃; for 15h; Kinetics; Product distribution;
mevastatin
73573-88-3

mevastatin

(3R,5R)-3,5-Dihydroxy-7-((1S,2S,8S,8aR)-8-hydroxy-2-methyl-1,2,6,7,8,8a-hexahydro-naphthalen-1-yl)-heptanoic acid

(3R,5R)-3,5-Dihydroxy-7-((1S,2S,8S,8aR)-8-hydroxy-2-methyl-1,2,6,7,8,8a-hexahydro-naphthalen-1-yl)-heptanoic acid

Conditions
ConditionsYield
With lithium hydroxide for 24h; Heating;
ethanol
64-17-5

ethanol

mevastatin
73573-88-3

mevastatin

3,5-dihydroxy-7-[2-methyl-8-(2-methyl-butyryloxy)-1,2,6,7,8,8a-hexahydro-naphthalen-1-yl]-heptanoic acid ethyl ester

3,5-dihydroxy-7-[2-methyl-8-(2-methyl-butyryloxy)-1,2,6,7,8,8a-hexahydro-naphthalen-1-yl]-heptanoic acid ethyl ester

Conditions
ConditionsYield
With potassium hydroxide
mevastatin
73573-88-3

mevastatin

(S)-2-Methyl-butyric acid (1S,4S,6S,7R,8S,8aR)-4-chloro-6-formyloxy-8-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,4,6,7,8,8a-octahydro-naphthalen-1-yl ester
153079-18-6

(S)-2-Methyl-butyric acid (1S,4S,6S,7R,8S,8aR)-4-chloro-6-formyloxy-8-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,4,6,7,8,8a-octahydro-naphthalen-1-yl ester

mevastatin
73573-88-3

mevastatin

Acetic acid (1S,7S,8S,8aR)-7-methyl-8-((3R,5S)-3,5,7-triacetoxy-heptyl)-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester

Acetic acid (1S,7S,8S,8aR)-7-methyl-8-((3R,5S)-3,5,7-triacetoxy-heptyl)-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: LiAlH4 / diethyl ether
2: pyridine, DMAP
View Scheme
mevastatin
73573-88-3

mevastatin

<4R-<4α(4R*,5R*),6α>>-5-<2-<6-<2-<<(1,1-dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-4-methyl-2-cyclohexen-1-one
116996-32-8

<4R-<4α(4R*,5R*),6α>>-5-<2-<6-<2-<<(1,1-dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-4-methyl-2-cyclohexen-1-one

Conditions
ConditionsYield
Multi-step reaction with 14 steps
1: 81 percent / LiAlH4 / tetrahydrofuran / 9 h / Ambient temperature
2: 92 percent / imidazole / dimethylformamide / 1 h
3: 89 percent / PPTS / CH2Cl2 / 0.17 h / 0 °C
4: 89 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 2 h / Ambient temperature
5: 1.) Li, CuCN / 1.) THF, 2.) THF, 4 h
6: 95 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 6 h / Ambient temperature
7: 84 percent / Et3N, DMAP / CH2Cl2 / 0.17 h / 0 °C
8: 98 percent / Pr4NRuO4, 4 Angstroem molecular sieves, 4-methylmorpholine N-oxide / CH2Cl2 / 6 h
9: 79 percent / LDA, Et3N / 0.42 h / -78 °C
10: 1.) m-CPBA, 2.) Bu4NF, AcOH
11: AcOH / methanol / 11 h
12: PPTS / 7.5 h
13: aq. NaIO4 / methanol / 23 h / Ambient temperature
14: PPTS / 2.5 h
View Scheme
Multi-step reaction with 13 steps
1: 81 percent / LiAlH4 / tetrahydrofuran / 9 h / Ambient temperature
2: 92 percent / imidazole / dimethylformamide / 1 h
3: 89 percent / PPTS / CH2Cl2 / 0.17 h / 0 °C
4: 89 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 2 h / Ambient temperature
5: 1.) Li, CuCN / 1.) THF, 2.) THF, 4 h
6: 95 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 6 h / Ambient temperature
7: 84 percent / Et3N, DMAP / CH2Cl2 / 0.17 h / 0 °C
8: 98 percent / Pr4NRuO4, 4 Angstroem molecular sieves, 4-methylmorpholine N-oxide / CH2Cl2 / 6 h
9: 1.) potassium bis(trimethylsilyl)amide, 2-(phenylsulfonyl)-3-(p-nitrophenyl)oxaziridine, 2.) Bu4NF / 1.) THF, toluene, -78 deg C, 30 min; -78 deg C, 30 min, 2.) THF, 30 min
10: AcOH / methanol / 11 h
11: PPTS / 7.5 h
12: aq. NaIO4 / methanol / 23 h / Ambient temperature
13: PPTS / 2.5 h
View Scheme
mevastatin
73573-88-3

mevastatin

<1S-<1α,7β,8β(4S*,6R*),8aβ>>-8-<2-<6-<2-<<(1,1-Dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-1,2,6,7,8,8a-hexahydro-7-methyl-1-naphthalenol
117065-48-2

<1S-<1α,7β,8β(4S*,6R*),8aβ>>-8-<2-<6-<2-<<(1,1-Dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-1,2,6,7,8,8a-hexahydro-7-methyl-1-naphthalenol

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 81 percent / LiAlH4 / tetrahydrofuran / 9 h / Ambient temperature
2: 92 percent / imidazole / dimethylformamide / 1 h
3: 89 percent / PPTS / CH2Cl2 / 0.17 h / 0 °C
View Scheme
mevastatin
73573-88-3

mevastatin

(4R,5R)-5-[(3R,5S)-7-(tert-Butyl-diphenyl-silanyloxy)-3,5-dihydroxy-heptyl]-4-methyl-cyclohex-2-enone

(4R,5R)-5-[(3R,5S)-7-(tert-Butyl-diphenyl-silanyloxy)-3,5-dihydroxy-heptyl]-4-methyl-cyclohex-2-enone

Conditions
ConditionsYield
Multi-step reaction with 13 steps
1: 81 percent / LiAlH4 / tetrahydrofuran / 9 h / Ambient temperature
2: 92 percent / imidazole / dimethylformamide / 1 h
3: 89 percent / PPTS / CH2Cl2 / 0.17 h / 0 °C
4: 89 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 2 h / Ambient temperature
5: 1.) Li, CuCN / 1.) THF, 2.) THF, 4 h
6: 95 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 6 h / Ambient temperature
7: 84 percent / Et3N, DMAP / CH2Cl2 / 0.17 h / 0 °C
8: 98 percent / Pr4NRuO4, 4 Angstroem molecular sieves, 4-methylmorpholine N-oxide / CH2Cl2 / 6 h
9: 79 percent / LDA, Et3N / 0.42 h / -78 °C
10: 1.) m-CPBA, 2.) Bu4NF, AcOH
11: AcOH / methanol / 11 h
12: PPTS / 7.5 h
13: aq. NaIO4 / methanol / 23 h / Ambient temperature
View Scheme
Multi-step reaction with 12 steps
1: 81 percent / LiAlH4 / tetrahydrofuran / 9 h / Ambient temperature
2: 92 percent / imidazole / dimethylformamide / 1 h
3: 89 percent / PPTS / CH2Cl2 / 0.17 h / 0 °C
4: 89 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 2 h / Ambient temperature
5: 1.) Li, CuCN / 1.) THF, 2.) THF, 4 h
6: 95 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 6 h / Ambient temperature
7: 84 percent / Et3N, DMAP / CH2Cl2 / 0.17 h / 0 °C
8: 98 percent / Pr4NRuO4, 4 Angstroem molecular sieves, 4-methylmorpholine N-oxide / CH2Cl2 / 6 h
9: 1.) potassium bis(trimethylsilyl)amide, 2-(phenylsulfonyl)-3-(p-nitrophenyl)oxaziridine, 2.) Bu4NF / 1.) THF, toluene, -78 deg C, 30 min; -78 deg C, 30 min, 2.) THF, 30 min
10: AcOH / methanol / 11 h
11: PPTS / 7.5 h
12: aq. NaIO4 / methanol / 23 h / Ambient temperature
View Scheme
mevastatin
73573-88-3

mevastatin

<1S-<1α(3R*,5S*),2α,8β,8aα>>-1<<(1,1-Dimethylethyl)diphenylsilyl>oxy>-7-(1,2,6,7,8,8a-hexahydro-8-hydroxy-2-methyl-1-naphthalenyl)-3,5-heptanediol
126060-27-3

<1S-<1α(3R*,5S*),2α,8β,8aα>>-1<<(1,1-Dimethylethyl)diphenylsilyl>oxy>-7-(1,2,6,7,8,8a-hexahydro-8-hydroxy-2-methyl-1-naphthalenyl)-3,5-heptanediol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 81 percent / LiAlH4 / tetrahydrofuran / 9 h / Ambient temperature
2: 92 percent / imidazole / dimethylformamide / 1 h
View Scheme
mevastatin
73573-88-3

mevastatin

<1aR-<1aα,4β,4aα,5α(4R*,6S*),6α>>-5-<2-<6-<2-<<(1,1-Dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-1a,2,4,4a,5,6-hexahydro-6-methyl-3H-naphth<1,8a-b>oxiren-4-ol
161466-61-1

<1aR-<1aα,4β,4aα,5α(4R*,6S*),6α>>-5-<2-<6-<2-<<(1,1-Dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-1a,2,4,4a,5,6-hexahydro-6-methyl-3H-naphth<1,8a-b>oxiren-4-ol

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 81 percent / LiAlH4 / tetrahydrofuran / 9 h / Ambient temperature
2: 92 percent / imidazole / dimethylformamide / 1 h
3: 89 percent / PPTS / CH2Cl2 / 0.17 h / 0 °C
4: 89 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 2 h / Ambient temperature
View Scheme
mevastatin
73573-88-3

mevastatin

(4R,7S,8S,8aR)-8-[(3R,5S)-7-(tert-Butyl-diphenyl-silanyloxy)-3,5-dihydroxy-heptyl]-2,4,4a-trihydroxy-7-methyl-3,4,4a,7,8,8a-hexahydro-2H-naphthalen-1-one

(4R,7S,8S,8aR)-8-[(3R,5S)-7-(tert-Butyl-diphenyl-silanyloxy)-3,5-dihydroxy-heptyl]-2,4,4a-trihydroxy-7-methyl-3,4,4a,7,8,8a-hexahydro-2H-naphthalen-1-one

Conditions
ConditionsYield
Multi-step reaction with 11 steps
1: 81 percent / LiAlH4 / tetrahydrofuran / 9 h / Ambient temperature
2: 92 percent / imidazole / dimethylformamide / 1 h
3: 89 percent / PPTS / CH2Cl2 / 0.17 h / 0 °C
4: 89 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 2 h / Ambient temperature
5: 1.) Li, CuCN / 1.) THF, 2.) THF, 4 h
6: 95 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 6 h / Ambient temperature
7: 84 percent / Et3N, DMAP / CH2Cl2 / 0.17 h / 0 °C
8: 98 percent / Pr4NRuO4, 4 Angstroem molecular sieves, 4-methylmorpholine N-oxide / CH2Cl2 / 6 h
9: 79 percent / LDA, Et3N / 0.42 h / -78 °C
10: 1.) m-CPBA, 2.) Bu4NF, AcOH
11: AcOH / methanol / 11 h
View Scheme
Multi-step reaction with 10 steps
1: 81 percent / LiAlH4 / tetrahydrofuran / 9 h / Ambient temperature
2: 92 percent / imidazole / dimethylformamide / 1 h
3: 89 percent / PPTS / CH2Cl2 / 0.17 h / 0 °C
4: 89 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 2 h / Ambient temperature
5: 1.) Li, CuCN / 1.) THF, 2.) THF, 4 h
6: 95 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 6 h / Ambient temperature
7: 84 percent / Et3N, DMAP / CH2Cl2 / 0.17 h / 0 °C
8: 98 percent / Pr4NRuO4, 4 Angstroem molecular sieves, 4-methylmorpholine N-oxide / CH2Cl2 / 6 h
9: 1.) potassium bis(trimethylsilyl)amide, 2-(phenylsulfonyl)-3-(p-nitrophenyl)oxaziridine, 2.) Bu4NF / 1.) THF, toluene, -78 deg C, 30 min; -78 deg C, 30 min, 2.) THF, 30 min
10: AcOH / methanol / 11 h
View Scheme
mevastatin
73573-88-3

mevastatin

<4R-<4α,7β,8β(4R*,6S*),8aβ>>-4-<2-<6-<2-<<(1,1-Dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-3,4,4a,7,8,8a-hexahydro-2,4,4a-trihydroxy-7-methyl-1(2H)naphthalenone

<4R-<4α,7β,8β(4R*,6S*),8aβ>>-4-<2-<6-<2-<<(1,1-Dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-3,4,4a,7,8,8a-hexahydro-2,4,4a-trihydroxy-7-methyl-1(2H)naphthalenone

Conditions
ConditionsYield
Multi-step reaction with 12 steps
1: 81 percent / LiAlH4 / tetrahydrofuran / 9 h / Ambient temperature
2: 92 percent / imidazole / dimethylformamide / 1 h
3: 89 percent / PPTS / CH2Cl2 / 0.17 h / 0 °C
4: 89 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 2 h / Ambient temperature
5: 1.) Li, CuCN / 1.) THF, 2.) THF, 4 h
6: 95 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 6 h / Ambient temperature
7: 84 percent / Et3N, DMAP / CH2Cl2 / 0.17 h / 0 °C
8: 98 percent / Pr4NRuO4, 4 Angstroem molecular sieves, 4-methylmorpholine N-oxide / CH2Cl2 / 6 h
9: 79 percent / LDA, Et3N / 0.42 h / -78 °C
10: 1.) m-CPBA, 2.) Bu4NF, AcOH
11: AcOH / methanol / 11 h
12: PPTS / 7.5 h
View Scheme
Multi-step reaction with 11 steps
1: 81 percent / LiAlH4 / tetrahydrofuran / 9 h / Ambient temperature
2: 92 percent / imidazole / dimethylformamide / 1 h
3: 89 percent / PPTS / CH2Cl2 / 0.17 h / 0 °C
4: 89 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 2 h / Ambient temperature
5: 1.) Li, CuCN / 1.) THF, 2.) THF, 4 h
6: 95 percent / NaHCO3, t-BuOOH, VO(acac)2 / benzene / 6 h / Ambient temperature
7: 84 percent / Et3N, DMAP / CH2Cl2 / 0.17 h / 0 °C
8: 98 percent / Pr4NRuO4, 4 Angstroem molecular sieves, 4-methylmorpholine N-oxide / CH2Cl2 / 6 h
9: 1.) potassium bis(trimethylsilyl)amide, 2-(phenylsulfonyl)-3-(p-nitrophenyl)oxaziridine, 2.) Bu4NF / 1.) THF, toluene, -78 deg C, 30 min; -78 deg C, 30 min, 2.) THF, 30 min
10: AcOH / methanol / 11 h
11: PPTS / 7.5 h
View Scheme

Mevastatin History

MEVASTATIN(73573-88-3) was the first compound isolated in the 70s during research into HMG-CoA reductase inhibitors produced by a mould Penicillium citrinum

Mevastatin Specification

The IUPAC name of Mevastatin is [(1S,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate. With the CAS registry number 73573-88-3, it is also named as Compactin. The product's categories are Active Pharmaceutical Ingredients; Various Metabolites and Impurities; Metabolites; Pharmaceuticals; HMG-CoA Reductase, and the other registry numbers are 58948-09-7; 60478-65-1. Besides, it is off-white solid, which should be stored in sealed containers in a cool, dry place at 2-8 °C away from oxidizing agents. In addition, its molecular formula is C23H34O5 and molecular weight is 390.52.

The other characteristics of this product can be summarized as: (1)ACD/LogP: 3.57; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 3.57; (4)ACD/LogD (pH 7.4): 3.57; (5)ACD/BCF (pH 5.5): 306.24; (6)ACD/BCF (pH 7.4): 306.24; (7)ACD/KOC (pH 5.5): 2094.71; (8)ACD/KOC (pH 7.4): 2094.71; (9)#H bond acceptors: 5; (10)#H bond donors: 1; (11)#Freely Rotating Bonds: 8; (12)Index of Refraction: 1.535; (13)Molar Refractivity: 107.1 cm3; (14)Molar Volume: 343.8 cm3; (15)Surface Tension: 44.5 dyne/cm; (16)Density: 1.13 g/cm3; (17)Flash Point: 186.5 °C; (18)Melting Point: 151-153 °C; (19)Solubility: DMSO: 20 mg/mL; (20)Enthalpy of Vaporization: 96.1 kJ/mol; (21)Boiling Point: 555 °C at 760 mmHg; (22)Vapour Pressure: 1.25E-14 mmHg at 25 °C.

Preparation of Mevastatin: this chemical can be prepared by 2-Methyl-butyric acid 8-[2-(4,6-dihydroxy-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester.



This reaction needs Ag2CO3/Celite and Toluene at temperature of 95 °C. The reaction time is 2 hours. The yield is 61 %.

Uses of Mevastatin: this chemical is a hypolipidemic agent. It is also used as a HMG-CoA reductase inhibitor. Similarly, it can be used to produce Desmethylmonacolin J.



This reaction needs aq. LiOH by heating for 1 day. The yield is 75 %.

When you are using this chemical, please be cautious about it as the following: it is very toxic by inhalation, in contact with skin and if swallowed. Please do not breathe dust. And you should wear suitable protective clothing, gloves and eye/face protection to avoid contact with skin and eyes. Moreover, in case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)

People can use the following data to convert to the molecule structure.
(1)SMILES: O=C(O[C@@H]1[C@H]3C(=C/CC1)\C=C/[C@@H]([C@@H]3CC[C@H]2OC(=O)C[C@H](O)C2)C)[C@@H](C)CC
(2)InChI: InChI=1/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1
(3)InChIKey: AJLFOPYRIVGYMJ-INTXDZFKBX

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
mouse LD oral > 2gm/kg (2000mg/kg)   Journal of Antibiotics. Vol. 29, Pg. 1346, 1976.
mouse LD50 intraperitoneal 500mg/kg (500mg/kg)   Journal of Antibiotics. Vol. 29, Pg. 1346, 1976.

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View